酒精使用障碍与酒精相关的肝病患者的药物治疗:一个范围审查
Manisha Jogendran1, Louis Huynh1, Jennifer A Flemming1,2
1Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Canadian journal of gastroenterology & hepatology
|April 14, 2025
概括
酒精使用障碍 (AUD) 的药物治疗可以改善酒精相关肝病 (ALD) 患者的肝脏结果. 有限的研究表明,这些药物可以降低肝脏衰减和死亡率,但需要更多的研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 成 药物 药物 药物 药物
- 临床药理学 临床药理学
背景情况:
- 酒精相关性肝病 (ALD) 是肝硬化的主要原因.
- 对酒精使用障碍 (AUD) 的药物治疗可以提高肝硬化患者的禁欲.
- 关于AUD药疗对ALD患者肝脏特异性结局的影响的数据很少.
研究的目的:
- 对AUD药物治疗对ALD患者肝脏结局的影响进行范围审查.
- 为了确定AUD药疗对肝脏衰竭,死亡率,ALD进展和肝脏移植需求的影响.
主要方法:
- 对多个电子数据库进行了全面的范围审查.
- 包括调查AUD药物治疗和ALD患者随后的肝脏结局的研究.
- 评估的主要结果包括肝脏衰退,死亡率,疾病进展和移植需求.
主要成果:
- 在2521项选研究中,选择了3项,包括45,948名患者 (98%是男性,平均年龄为58.7).
- 只有5%的患者接受了针对AUD的药物治疗.
- 在3项纳入研究中的2项中,AUD药疗与降低肝脏衰竭和死亡率有关.
结论:
- 有很少的研究研究了AUD药物治疗和ALD结果之间的关系.
- 目前的证据表明,AUD的药物治疗可能会对ALD患者的肝脏结果产生积极影响.
- 进一步的前性研究对于验证和阐明AUD药物治疗与改善肝脏结果之间的关联至关重要.
相关概念视频
Enzyme Inhibition
77.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.5K
Drug Therapy
30
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
30
Psychosis: Goals of Pharmacotherapy
96
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
96
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
CNS Depressants: Alcohol and Nicotine
156
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
156
Drug Abuse and Addiction: Pharmacological Phenomena
410
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
410


